Functional/JJ
Modification/NN
of/IN
a/DT
Specific/JJ
RNA/NN
with/IN
Targeted/VBN
./.
====================
Trans-Splicing/VBG
====================
The/DT
self-splicing/JJ
group/NN
I/NN
intron/NN
from/IN
Tetrahymena/NN
====================
thermophi/a/DT
has/VBZ
been/VBN
demonstrated/VBN
to/TO
perform/VB
splicing/NN
reaction/NN
with/IN
its/PRP$
substrate/NN
RNA/NN
in/IN
the/DT
trans/JJ
configuration/NN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
explored/VBD
the/DT
potential/JJ
use/NN
of/IN
the/DT
/rans-splicing/JJ
group/NN
I/NN
ribozymes/NNS
to/TO
replace/VB
a/DT
specific/JJ
RNA/NN
with/IN
a/DT
new/JJ
RNA/NN
that/DT
exerts/VBZ
any/DT
new/JJ
function/NN
we/PRP
want/VBD
to/TO
introduce/VB
./.
====================
We/PRP
have/VBP
chosen/NN
thymidine/NN
phosphorylase/NN
(/(
TP/NN
)/)
RNA/NN
as/IN
a/DT
target/NN
RNA/NN
that/DT
is/VBZ
known/VBN
as/IN
a/DT
valid/JJ
cancer/NN
prognostic/JJ
factor/NN
./.
====================
Cancer-specific/JJ
expression/NN
of/IN
TP/NN
RNA/NN
was/VBD
first/JJ
evaluated/VBD
with/IN
RT-PCR/NN
analysis/NN
of/IN
RNA/NN
from/IN
patients/NNS
with/IN
gastric/JJ
cancer/NN
./.
====================
We/PRP
determined/VBD
next/RB
which/WDT
regions/NNS
of/IN
the/DT
TP/NN
RNA/NN
are/VBP
accessible/JJ
to/TO
ribozymes/NNS
by/IN
employing/VBG
an/DT
RNA/NN
mapping/NN
strategy/NN
,/,
and/CC
found/VBD
that/IN
the/DT
leader/NN
sequences/NNS
upstream/RB
of/IN
the/DT
AUG/NN
start/VBP
codon/NN
appeared/VBD
to/TO
be/VB
particularly/RB
accessible/JJ
./.
====================
A/DT
specific/JJ
ribozyme/NN
recognizing/VBG
the/DT
most/JJS
accessible/JJ
sequence/NN
in/IN
the/DT
TP/NN
RNA/NN
with/IN
firefly/RB
luciferase/NN
transcript/NN
as/IN
a/DT
3/CD
’/NN
exon/NN
was/VBD
then/RB
developed/VBD
./.
====================
The/DT
specific/JJ
/rans-splicing/VBG
ribozyme/NN
transferred/VBN
an/DT
intended/JJ
3/CD
’/NN
exon/NN
tag/NN
sequence/NN
onto/IN
the/DT
targeted/VBN
TP/NN
transcripts/NNS
,/,
resulting/VBG
in/IN
a/DT
more/RBR
than/IN
two/CD
fold/JJ
induction/NN
of/IN
the/DT
reporter/NN
activity/NN
in/IN
the/DT
presence/NN
of/IN
TP/NN
RNA/NN
in/IN
mammalian/JJ
cells/NNS
,/,
compared/VBN
to/TO
the/DT
absence/NN
of/IN
the/DT
target/NN
RNA/NN
./.
====================
These/DT
results/NNS
suggest/VBP
that/IN
the/DT
Tetrahymena/NN
ribozyme/NN
can/MD
be/VB
a/DT
potent/JJ
anti-cancer/JJ
agent/NN
to/TO
modify/VB
TP/NN
RNAs/NNS
in/IN
tumors/NNS
with/IN
a/DT
new/JJ
RNA/NN
harboring/VBG
anti-cancer/JJ
activity/NN
./.
====================
The/DT
self-splicing/JJ
group/NN
I/NN
intron/NN
from/IN
Tetrahymena/NNP
thermophila/DT
has/VBZ
been/VBN
previously/RB
shown/VBN
to/TO
to/7/DT
$/NNP
-splice/JJ
an/DT
exon/NN
attached/VBD
to/TO
its/PRP$
3/CD
’/NN
end/NN
onto/IN
a/DT
separate/JJ
target/NN
RNA/NN
not/RB
only/RB
in/IN
test/NN
tube/NN
(/(
Been/NNP
and/CC
Cech/JJ
,/,
1986/CD
)/)
but/CC
also/RB
in/IN
E./FW
coii/FW
(/(
Sullenger/NNP
and/CC
Cech/JJ
,/,
1994/CD
)/)
and/CC
mammalian/JJ
cells/NNS
(/(
Jones/NNS
et/FW
at/IN
,/,
1996/CD
)/)
./.
====================
Moreover/RB
,/,
the/DT
Zrans-splicing/JJ
ribozymes/NNS
have/VBP
been/VBN
demonstrated/VBN
to/TO
revise/VB
mutant/JJ
transcripts/NNS
associated/VBN
with/IN
several/JJ
human/JJ
genetic/JJ
and/CC
malignant/JJ
diseases/NNS
(/(
Lan/JJ
et/FW
ai/FW
,/,
1998/CD
;/:
Phylactou/NNP
et/FW
at/IN
,/,
1998/CD
;/:
Watanabe/NNP
and/CC
Sullenger/NNP
,/,
2000/CD
;/:
Shin/NN
et/FW
a/DT
!/JJ
./.
,/,
2002/CD
;/:
Rogers/NNS
et/FW
ai./FW
,/,
2002/CD
)/)
and/CC
selectively/RB
replace/RB
hepatitis/NN
C/NN
virus/NN
(/(
HCV/NN
)/)
transcripts/NNS
with/IN
a/DT
new/JJ
RNA/NN
that/IN
exerts/VBZ
anti-HCV/JJ
activity/NN
(/(
Ryu/NNP
et/FW
ai./FW
,/,
2003/CD
)/)
./.
====================
These/DT
imply/VBP
that/IN
frans-splicing/VBG
ribozymes/NNS
could/MD
be/VB
potentially/RB
used/VBN
for/IN
the/DT
functional/JJ
modification/NN
of/IN
any/DT
target/NN
RNA/NN
associated/VBN
human/JJ
diseases/NNS
with/IN
a/DT
new/JJ
RNA/NN
encoding/VBG
therapeutic/JJ
activity/NN
./.
====================
Thymidine/DT
phosphorylase/NN
(/(
TP/NN
)/)
,/,
which/WDT
is/VBZ
identical/JJ
to/TO
the/DT
platelet-derived/JJ
endothelial/JJ
cell/NN
growth/NN
factor/NN
(/(
PD-ECGF/NN
)/)
(/(
lltzsch/RB
et/FW
ai/FW
„/NNP
1985/CD
;/:
Furukawa/RB
et/FW
ai./FW
,/,
1992/CD
)/)
,/,
is/VBZ
expressed/VBN
at/IN
much/RB
higher/JJR
levels/NNS
in/IN
a/DT
wide/JJ
variety/NN
of/IN
tumors/NNS
,/,
compared/VBN
with/IN
adjacent/JJ
normal/JJ
tissues/NNS
(/(
Luccioni/NNP
et/FW
ai./FW
,/,
1994/CD
;/:
Fox/NNP
et/FW
at/IN
,/,
1995/CD
;/:
Takebayashi/NNP
et/FW
at/IN
,/,
1996/CD
)/)
./.
====================
Thus/RB
,/,
TP/NN
is/VBZ
a/DT
valid/JJ
hallmark/NN
of/IN
cancer/NN
./.
====================
Moreover/RB
,/,
TP/NN
could/MD
be/VB
an/DT
important/JJ
target/NN
for/IN
cancer/NN
therapies/NNS
since/IN
TP/NN
has/VBZ
angiogenic/JJ
activity/NN
in/IN
vivo/FW
(/(
Brown/JJ
et/FW
ai./FW
,/,
2000/CD
)/)
,/,
enhances/VBZ
tumor/NN
progression/NN
,/,
and/CC
confers/VBZ
resistance/NN
to/TO
apoptotic/JJ
signal/NN
pathways/NNS
(/(
Ikeda/NN
et/FW
ai/FW
„/CD
2002/CD
,/,
2003/CD
;/:
Mori/NNP
et/FW
ai./FW
,/,
2002/CD
)/)
,/,
====================
Here/RB
,/,
we/PRP
investigated/VBD
whether/IN
group/NN
l-based/VBD
ribozymes/NNS
could/MD
be/VB
utilized/VBN
to/TO
modify/VB
TP/NN
RNA/NN
in/IN
cells/NNS
to/TO
express/VB
the/DT
intended/JJ
sequences/NNS
tagged/VBN
to/TO
their/PRP$
3/CD
'/``
end/NN
by/IN
targeted/VBN
/ra/7s^-splicing/VBG
./.
====================
To/TO
this/DT
effect/NN
,/,
we/PRP
first/RB
confirm/VBP
the/DT
expression/NN
pattern/NN
of/IN
TP/NN
RNA/NN
in/IN
cancer/NN
patients/NNS
./.
====================
We/PRP
next/RB
identified/VBD
most/JJS
accessible/JJ
sites/NNS
in/IN
TP/NN
RNA/NN
to/TO
the/DT
ribozymes/NNS
and/CC
constructed/VBD
a/DT
specific/JJ
ribozyme/NN
recognizing/VBG
the/DT
site/NN
./.
====================
Moreover/RB
,/,
we/PRP
determined/VBD
if/IN
the/DT
ribozymes/NNS
could/MD
selectively/RB
induce/VBP
a/DT
new/JJ
reporter/NN
activity/NN
in/IN
TP-expressing/JJ
cells/NNS
by/IN
targeted/VBN
frans-splicing/VBG
./.
====================
Enzymes/NNS
arid/NN
reagents/NNS
for/IN
RT-PCR/NN
,/,
in/IN
vitro/FW
transcription/NN
====================
reaction/NN
,/,
or/CC
cloning/VBG
were/VBD
purchased/VBN
from/IN
Roche/DT
Applied/VBN
Science/NNP
or/CC
domestic/JJ
suppliers/NNS
,/,
sequencing/NN
reagents/NNS
from/IN
PE/NN
Applied/VBN
Biosystem/NN
./.
====================
Argininamide/NN
and/CC
most/JJS
of/IN
other/JJ
chemicals/NNS
came/VBD
from/IN
Sigma/NN
Chemical/JJ
Co./NN
DMEM/NN
tissue/NN
culture/NN
media/NNS
and/CC
fetal/JJ
bovine/NN
serum/NN
were/VBD
obtained/VBN
from/IN
GIBCO/NN
./.
====================
Surgical/JJ
samples/NNS
of/IN
11/CD
paired/JJ
normal/JJ
and/CC
tumor/NN
tissues/NNS
were/VBD
collected/VBN
from/IN
patients/NNS
undergoing/VBG
gastric/JJ
cancer/NN
surgery/NN
at/IN
the/DT
Department/JJ
of/IN
Surgery/NN
,/,
Seoul/JJ
National/JJ
University/NN
Hospital/JJ
./.
====================
Immediately/RB
after/IN
removal/NN
,/,
all/DT
of/IN
the/DT
tissues/NNS
for/IN
molecular/JJ
analysis/NN
were/VBD
put/RB
in/IN
liquid/JJ
nitrogen/NN
and/CC
stored/VBD
at/IN
-80°C/NN
until/IN
use/NN
./.
====================
Total/JJ
cellular/JJ
RNA/NN
was/VBD
extracted/VBN
from/IN
frozen/VBN
tissues/NNS
by/IN
using/VBG
the/DT
Tri/NN
reagent/JJ
(/(
Molecular/JJ
Research/NN
Center/JJ
,/,
Inc/NNP
)/)
according/VBG
to/TO
the/DT
manufactures/NNS
instruction/NN
and/CC
then/RB
treated/VBN
with/IN
DNase/NN
I/CD
to/TO
remove/VB
genomic/JJ
DNA/NN
,/,
Two/CD
/zg/JJ
of/IN
total/JJ
RNA/NN
was/VBD
reverse/JJ
transcribed/VBN
into/IN
cDNA/NN
with/IN
MMLV/NN
reverse/JJ
transcriptase/NN
and/CC
oligo/JJ
(/(
dT/JJ
)/)
i2-is/VBZ
./.
====================
Equal/JJ
amounts/NNS
of/IN
cDNA/NN
was/VBD
subsequently/RB
amplified/VBN
by/IN
PCR/NN
in/IN
50/CD
ji\/RB
reaction/NN
volume/NN
containing/VBG
1X/CD
PCR/NN
buffer/NN
,/,
200/CD
/zM/NN
dNTP/NN
,/,
1.5/CD
mM/NN
MgCh/NN
,/,
0.2/CD
/zM/NN
of/IN
each/DT
specific/JJ
primer/NN
set/NN
and/CC
====================
2.5/CD
U/NNP
Taq/NN
DNA/NN
polymerase/NN
./.
====================
Control/NN
amplification/NN
was/VBD
performed/VBN
with/IN
//JJ
?/.
-actin/NN
./.
====================
Amplified/VBN
products/NNS
were/VBD
electrophoresed/VBN
on/IN
1/CD
%/NN
agarose/NN
gel/NN
./.
====================
The/DT
mapping/VBG
library/NN
,/,
called/VBN
GN5/NN
ribozyme/NN
library/NN
,/,
was/VBD
constructed/VBN
by/IN
randomizing/VBG
internal/JJ
guide/NN
sequence/NN
(/(
IGS/NN
)/)
of/IN
the/DT
Tetrahymena/NN
group/NN
I/NN
intron/NN
so/RB
that/IN
the/DT
5/CD
’/NN
end/NN
of/IN
the/DT
ribozyme/NN
in/IN
the/DT
library/NN
began/VBD
with/IN
5-GNNNNN-3/CD
’/NNP
,/,
where/WRB
G/NN
represents/VBZ
guanine/NN
and/CC
N/NN
represents/VBZ
equimolar/JJ
amounts/NNS
of/IN
the/DT
four/CD
nucleotides/NNS
(/(
nt/NNS
)/)
,/,
as/IN
described/VBN
(/(
Lan/JJ
et/FW
a/DT
!/JJ
./.
,/,
1998/CD
)/)
./.
====================
TP/NN
RNA/NN
,/,
target/NN
RNA/NN
,/,
was/VBD
generated/VBN
by/IN
in/FW
vitro/FW
transcription/NN
using/VBG
T7/NN
RNA/NN
polymerase/NN
with/IN
a/DT
cDNA/NN
clone/NN
of/IN
TP/NN
(/(
Ishikawa/NNP
et/FW
ai/FW
„/CD
1989/CD
,/,
a/DT
kind/JJ
gift/JJ
from/IN
C.-H./NNP
Heldin/NN
,/,
Ludwig/NN
Institute/JJ
,/,
Sweden/JJ
)/)
./.
====================
To/TO
map/VB
the/DT
TP/NN
RNA/NN
,/,
50/CD
nM/NN
of/IN
the/DT
GN5/NN
ribozyme/NN
library/NN
was/VBD
incubated/VBN
at/IN
37°C/NN
for/IN
3/CD
h/NN
under/IN
splicing/NN
condition/NN
(/(
50/CD
mM/NN
HEPES/NN
,/,
pH/NN
7.0/CD
,/,
150/CD
mM/NN
NaCI/NN
,/,
5/CD
mM/NN
MgCh/NNP
)/)
in/IN
the/DT
presence/NN
of/IN
a/DT
guanosine/NN
(/(
100/CD
/zM/NN
)/)
with/IN
100/CD
nM/NN
of/IN
the/DT
TP/NN
RNA/NN
./.
====================
The/DT
reaction/NN
products/NNS
were/VBD
reverse-transcribed/VBN
at/IN
37°C/NN
for/IN
30/CD
min/NN
in/IN
the/DT
presence/NN
of/IN
argininamide/NN
(/(
10/CD
mM/NN
)/)
with/IN
a/DT
3/CD
’/NN
tag/NN
primer/NN
specific/JJ
for/IN
the/DT
ribozyme/NN
’/CD
s/NNS
3/CD
’/NN
exon/NN
IacZ/NN
sequence/NN
(/(
5-ATGTGCTGCAAGGCGATT-3/CD
’/CD
)/)
(/(
Jones/NNS
et/FW
ai/FW
„/CD
1996/CD
)/)
./.
====================
cDNAs/NNS
were/VBD
then/RB
amplified/VBD
by/IN
PCR/NN
for/IN
35/CD
cycles/NNS
using/VBG
the/DT
same/JJ
3/CD
’/NN
primer/NN
and/CC
a/DT
5/CD
’/NN
primer/NN
encompassing/VBG
the/DT
5/CD
end/NN
of/IN
target/NN
TP/NN
RNA/NN
(/(
5/CD
’/NN
-CCGGAATTCTAATACGACTCACTA/NN
TAGGGCAGTGGACCGCTGTG-3/NN
’/CD
)/)
./.
====================
The/DT
amplified/VBN
trans—/VBP
====================
splicing/NN
products/NNS
were/VBD
cloned/VBN
into/IN
pUC19/NN
vector/NN
and/CC
sequenced/VBN
using/VBG
the/DT
dideoxy/JJ
termination/NN
method/NN
with/IN
automatic/JJ
sequencer/NN
(/(
ABI/LS
310/CD
Genetic/JJ
Analyzer/NN
)/)
./.
====================
Specific/JJ
ribozymes/NNS
such/JJ
as/IN
Rib73/NN
that/IN
recognize/VBP
the/DT
uridine/JJ
at/IN
position/NN
73/CD
on/IN
the/DT
TP/NN
RNA/NN
were/VBD
generated/VBN
by/IN
in/FW
vitro/FW
transcription/NN
of/IN
DNA/NN
templates/NNS
which/WDT
were/VBD
created/VBN
from/IN
pT7L-21/NN
by/IN
PCR/NN
with/IN
a/DT
5/CD
’/NN
primer/NN
containing/VBG
the/DT
T7/NN
promoter/NN
and/CC
the/DT
ribozyme/NN
’/CD
s/NNS
IGS/NN
and/CC
with/IN
a/DT
3/CD
’/NN
primer/NN
specific/JJ
for/IN
the/DT
3/CD
'/``
exon/NN
iacZ/NN
sequence/NN
./.
====================
The/DT
pT7L-21/NN
vector/NN
encodes/VBZ
a/DT
slightly/RB
shortened/JJ
version/NN
of/IN
the/DT
natural/JJ
group/NN
I/NN
intron/NN
from/IN
Tetrahymena/NN
,/,
called/VBN
L-21/NN
(/(
Sullenger/NN
and/CC
Cech/JJ
,/,
1994/CD
)/)
./.
====================
The/DT
IGS/NN
on/IN
the/DT
L-21/NN
/ra/7S-splicing/VBG
ribozyme/NN
(/(
5-GGAGGG-3/CD
’/CD
)/)
was/VBD
exchanged/VBN
with/IN
5-GGCCCA/NN
in/IN
Rib73/NN
./.
====================
In/IN
addition/NN
,/,
inactive/JJ
ribozyme/NN
,/,
R/NN
(/(
d/FW
)/)
73/CD
,/,
which/WDT
is/VBZ
devoid/JJ
of/IN
the/DT
catalytic/JJ
core/NN
of/IN
the/DT
enzyme/NN
(/(
Sullenger/NN
and/CC
Cech/JJ
,/,
1994/CD
)/)
,/,
was/VBD
constructed/VBN
as/IN
negative/JJ
controls/NNS
./.
====================
To/TO
construct/VB
enhanced/VBD
ribozyme/NN
expression/NN
vector/NN
,/,
complementary/JJ
oligonucleotides/NNS
containing/VBG
an/DT
extended/JJ
P1/NN
plus/CC
a/DT
7-nt-long/JJ
P10/NN
helix/NN
and/CC
300/CD
nt-long/JJ
PCR-amplified/JJ
sequence/NN
for/IN
the/DT
antisense/JJ
region/NN
against/IN
TP/NN
gene/NN
were/VBD
inserted/VBN
upstream/RB
of/IN
IGS/NN
of/IN
Rib73/NN
./.
====================
In/IN
addition/NN
,/,
3/CD
’/NN
exon/NN
of/IN
the/DT
modified/VBN
Rib73/NN
was/VBD
replaced/VBN
with/IN
a/DT
cDNA/NN
sequence/NN
encoding/VBG
firefly/RB
luciferase/NN
gene/NN
(/(
Flue/NN
)/)
./.
====================
DNA/NN
fragment/NN
consisting/VBG
of/IN
Rib73/NN
sequence/NN
with/IN
the/DT
extended/JJ
IGS/NN
plus/CC
Flue/NN
ORF/NN
was/VBD
inserted/VBN
between/IN
the/DT
EcoRI/NN
and/CC
Xbd/JJ
sites/NNS
of/IN
pSEAP/NN
that/DT
encodes/VBZ
alkaline/NN
phosphatase/NN
under/IN
SV40/NN
promoter/NN
(/(
Clontech/NN
)/)
to/TO
generate/VB
Rib73AS-Fluc/NN
./.
====================
For/IN
in/IN
vitro/FW
trans-sp\/VBP
icing/VBG
reaction/NN
assay/NN
of/IN
ribozymes/NNS
,/,
Rib73/NN
(/(
100/CD
nM/NN
)/)
were/VBD
incubated/VBN
at/IN
37°C/NN
for/IN
3/CD
h/NN
under/IN
splicing/NN
conditions/NNS
with/IN
TP/NN
RNA/NN
(/(
10/CD
nM/NN
)/)
./.
====================
The/DT
resulting/VBG
RNA/NN
was/VBD
reverse-transcribed/VBN
at/IN
37°C/NN
for/IN
30/CD
min/NN
in/IN
the/DT
presence/NN
of/IN
argininamide/NN
(/(
10/CD
mM/NN
)/)
with/IN
a/DT
3/CD
’/NN
primer/NN
specific/JJ
for/IN
the/DT
ribozyme/NN
’/CD
s/NNS
3/CD
’/NN
exon/NN
iacZ/NN
sequence/NN
as/IN
described/VBN
above/IN
./.
====================
cDNAs/NNS
were/VBD
then/RB
amplified/VBD
by/IN
PCR/NN
for/IN
35/CD
cycles/NNS
with/IN
the/DT
same/JJ
3/CD
’/NN
primer/NN
and/CC
with/IN
a/DT
5/CD
’/NN
primer/NN
specific/JJ
for/IN
the/DT
5/CD
’/NN
end/NN
of/IN
TP/NN
RNA/NN
./.
====================
The/DT
reaction/NN
products/NNS
were/VBD
analyzed/VBN
on/IN
a/DT
3/CD
%/NN
agarose/NN
gel/NN
./.
====================
RT-PCR/NN
products/NNS
were/VBD
eluted/VBN
from/IN
the/DT
gel/NN
,/,
cloned/VBN
onto/IN
pUC19/NN
vector/NN
,/,
and/CC
then/RB
sequenced/VBN
with/IN
the/DT
dideoxy/JJ
termination/NN
method/NN
./.
====================
NIH3T3/NN
cells/NNS
were/VBD
plated/VBN
at/IN
3.0/CD
X/NN
10/CD
5/CD
cells/NNS
per/FW
well/RB
in/IN
35/CD
mm/NN
dishes/NNS
24/CD
h/NN
prior/JJ
to/TO
transfection/NN
./.
====================
TP/NN
expression/NN
vectors/NNS
,/,
TP-fl/JJ
or/CC
TP-orf/NN
,/,
were/VBD
generated/VBN
by/IN
cloning/VBG
of/IN
the/DT
full-length/JJ
cDNA/NN
sequence/NN
or/CC
ORF/NN
sequence/NN
of/IN
TP/NN
,/,
respectively/RB
,/,
into/IN
the/DT
downstream/JJ
region/NN
of/IN
CMV/NN
promoter/NN
====================
of/IN
pCDNA/NN
./.
====================
The/DT
cells/NNS
were/VBD
cotransfected/VBN
with/IN
0.1/CD
nQ/NN
TP—fl/JJ
or/CC
0.1/CD
nQ/NN
TP-orf/NN
along/IN
with/IN
0.1/CD
nQ/NN
pRLuc/NN
encoding/VBG
renillar/JJ
luciferase/NN
as/IN
internal/JJ
control/JJ
and/CC
with/IN
1.8/CD
nQ/NN
control/NN
vector/NN
(/(
pSEAP/NN
)/)
or/CC
pRib73AS-Fluc/JJ
using/VBG
4/CD
/zl/JJ
lipofectamine/NN
(/(
GIBCO/BRL/NN
)/)
./.
====================
Cell/NN
lysates/NNS
were/VBD
harvested/VBN
24/CD
h/NN
after/IN
transfection/NN
,/,
and/CC
reporter/NN
gene/NN
activities/NNS
were/VBD
assessed/VBN
by/IN
measuring/VBG
relative/JJ
light/NN
units/NNS
using/VBG
a/DT
luminometer/NN
TD-20/20/CD
(/(
Turner/NN
Designs/NNS
Instrument/JJ
)/)
and/CC
dual­/IN
luciferase/NN
reporter/NN
assay/NN
system/NN
(/(
Promega/NN
)/)
./.
====================
For/IN
trans-/NN
splicing/NN
reaction/NN
in/IN
cells/NNS
,/,
NIH3T3/NN
cells/NNS
were/VBD
mock-/JJ
transfected/VBN
or/CC
cotransfected/VBN
with/IN
0.2/CD
ng/NN
TP-fl/JJ
with/IN
or/CC
without/IN
1.8/CD
ng/NN
pRib73AS-Fluc/NN
or/CC
pR/NN
(/(
d/FW
)/)
73AS-Fluc/JJ
./.
====================
Total/JJ
RNA/NN
was/VBD
isolated/VBN
from/IN
the/DT
cells/NNS
24/CD
h/NN
after/IN
transfection/NN
with/IN
guanidine/NN
isothiocyanate/NN
(/(
Feramisco/NN
et/FW
a//FW
„/CD
1982/CD
)/)
supplemented/VBD
with/IN
20/CD
mM/NN
EDTA/NN
./.
====================
RNA/NN
(/(
5/CD
//g/NN
)/)
was/VBD
reverse/JJ
transcribed/VBN
with/IN
a/DT
primer/NN
specific/JJ
for/IN
the/DT
3/CD
’/NN
tagging/VBG
Flue/NN
sequence/NN
in/IN
the/DT
presence/NN
of/IN
10/CD
mM/NN
L-argininamide/NN
./.
====================
The/DT
resulting/VBG
cDNAs/NNS
were/VBD
amplified/VBN
for/IN
40/CD
cycles/NNS
with/IN
a/DT
5/CD
’/NN
primer/NN
specific/JJ
for/IN
the/DT
/rans-splicing/JJ
junction/NN
(/(
5-CCGGAATTCCCGGGTACCTGGGCTCGA-3/CD
’/CD
)/)
and/CC
with/IN
a/DT
3/CD
’/NN
-primer/NN
specific/JJ
for/IN
the/DT
3/CD
’/NN
exon/NN
sequence/NN
./.
====================
TP/NN
expression/NN
pattern/NN
in/IN
gastric/JJ
cancer/NN
patients/NNS
====================
We/PRP
compared/VBD
the/DT
pattern/NN
of/IN
TP/NN
gene/NN
expression/NN
between/IN
gastric/JJ
tumor/NN
tissue/NN
and/CC
the/DT
adjacent/JJ
non/JJ
cancerous/JJ
normal/JJ
gastric/JJ
mucosa/NN
obtained/VBN
from/IN
11/CD
patients/NNS
with/IN
gastric/JJ
carcinoma/NN
using/VBG
RT-PCR/NN
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
TP/NN
was/VBD
expressed/VBN
at/IN
markedly/RB
higher/JJR
levels/NNS
in/IN
all/DT
gastric/JJ
cancer/NN
tissues/NNS
than/IN
the/DT
adjacent/JJ
normal/JJ
tissues/NNS
./.
====================
Even/RB
though/IN
much/RB
larger/JJR
samples/NNS
should/MD
be/VB
analyzed/VBN
,/,
this/DT
indicates/VBZ
that/IN
TP/NN
could/MD
be/VB
a/DT
candidate/NN
for/IN
a/DT
valid/JJ
marker/NN
in/IN
gastric/JJ
cancers/NNS
./.
====================
77ans-splicing/VBG
strategy/NN
of/IN
TP/NN
RNA/NN
with/IN
group/NN
I/NN
intron/NN
====================
In/IN
this/DT
study/NN
,/,
we/PRP
tested/VBD
if/IN
the/DT
group/NN
l-intron/NN
based/VBN
====================
ribozyme/NN
could/MD
replace/VB
and/CC
modify/VB
TP/NN
RNA/NN
with/IN
an/DT
intended/JJ
RNA/NN
with/IN
new/JJ
function/NN
./.
====================
In/IN
the/DT
splicing/NN
reaction/NN
,/,
the/DT
ribozyme/NN
recognizes/VBZ
target/NN
TP/NN
RNA/NN
by/IN
base/NN
pairing/JJ
to/TO
any/DT
accessible/JJ
uridine/NN
nucleotides/NNS
of/IN
the/DT
RNA/NN
through/IN
IGS/NN
of/IN
the/DT
ribozyme/NN
./.
====================
The/DT
ribozyme/NN
then/RB
cleaves/VBZ
the/DT
TP/NN
RNA/NN
,/,
releases/VBZ
the/DT
downstream/JJ
targeted/VBN
RNA/NN
sequence/NN
,/,
replaces/VBZ
the/DT
sequence/NN
with/IN
its/PRP$
3/CD
’/NN
exon/NN
,/,
and/CC
hence/RB
induce/VBP
a/DT
target/NN
RNA-dependent/JJ
new/JJ
gene/NN
activity/NN
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
Every/RB
uridine/NN
in/IN
TP/NN
RNA/NN
can/MD
be/VB
potentially/RB
targeted/VBN
by/IN
====================
Tetrahymena/NNS
group/NN
I/NN
intron/NN
through/IN
G-U/NN
base/NN
pairing/JJ
between/IN
the/DT
IGS/NN
of/IN
the/DT
ribozyme/NN
and/CC
the/DT
target/NN
RNA/NN
./.
====================
However/RB
,/,
only/RB
a/DT
limited/JJ
number/NN
of/IN
uridines/NNS
on/IN
the/DT
target/NN
RNA/NN
are/VBP
likely/JJ
accessible/JJ
to/TO
the/DT
ribozyme/NN
due/JJ
to/TO
the/DT
substrate/NN
RNA/NN
’/NN
s/NNS
tertiary/NN
structure/NN
and/CC
complex/NN
formation/NN
with/IN
proteins/NNS
in/IN
cellular/JJ
milieu/NN
(/(
Lan/JJ
et/FW
a/DT
!/JJ
„/CD
2000/CD
)/)
./.
====================
Thus/RB
,/,
an/DT
RNA/NN
mapping/NN
strategy/NN
was/VBD
carried/VBN
out/RP
to/TO
determine/VB
which/WDT
uridines/NNS
in/IN
the/DT
TP/NN
RNA/NN
are/VBP
accessible/JJ
to/TO
ribozymes/NNS
./.
====================
The/DT
mapping/NN
method/NN
was/VBD
based/VBN
on/IN
a/DT
Zrans-splicing/JJ
ribozyme/NN
library/NN
(/(
Lan/JJ
et/FW
a/DT
!/JJ
./.
,/,
1998/CD
,/,
2000/CD
;/:
Ryu/NNP
et/FW
a/./FW
,/,
2003/CD
)/)
and/CC
RNA/NN
tagging/VBG
(/(
Jones/NNS
et/FW
at./IN
,/,
1996/CD
)/)
as/IN
described/VBN
in/IN
Materials/NNS
and/CC
Methods/NNS
./.
====================
Sequence/NN
analyses/NNS
of/IN
the/DT
splicing/NN
junction/NN
sites/NNS
showed/VBD
that/IN
several/JJ
uridines/NNS
in/IN
the/DT
leader/NN
sequence/NN
upstream/RB
of/IN
the/DT
AUG/NN
start/VBP
codon/NN
(/(
position/NN
124/CD
nt/NNS
)/)
,/,
appeared/VBD
to/TO
be/VB
particularly/RB
accessible/JJ
(/(
Fig/NN
./.
====================
3A/NN
)/)
./.
====================
Especially/RB
,/,
the/DT
uridine/NN
at/IN
position/NN
73/CD
(/(
U73/NN
)/)
on/IN
TP/NN
RNA/NN
was/VBD
the/DT
most/JJS
frequently/RB
found/VBN
as/IN
the/DT
splicing/NN
site/NN
./.
====================
We/PRP
evaluated/VBD
several/JJ
different/JJ
ribozymes/NNS
for/IN
their/PRP$
/rans-splicing/JJ
abilities/NNS
,/,
then/RB
Rib73/NN
recognizing/VBG
U73/NN
on/IN
TP/NN
RNA/NN
reacted/VBD
with/IN
the/DT
target/NN
RNA/NN
with/IN
the/DT
highest/JJS
efficiency/NN
(/(
data/NNS
not/RB
shown/VBN
)/)
./.
====================
These/DT
observations/NNS
strongly/RB
indicate/VBP
that/IN
the/DT
relative/JJ
frans-splicing/NN
efficiency/NN
at/IN
the/DT
selected/VBN
sites/NNS
corresponds/VBZ
with/IN
the/DT
predicted/VBN
accessibility/NN
from/IN
the/DT
mapping/NN
analyses/NNS
and/CC
encourage/VBP
us/PRP
to/TO
focus/VB
on/IN
further/JJ
developing/VBG
and/CC
characterizing/VBG
Rib73/NN
./.
====================
To/TO
determine/VB
whether/IN
the/DT
specific/JJ
ribozyme/NN
,/,
Rib73/NN
,/,
employed/VBN
Zrar7s-splicing/VBG
reaction/NN
on/IN
the/DT
target/NN
TP/NN
RNA/NN
,/,
the/DT
active/JJ
or/CC
inactive/JJ
ribozymes/NNS
were/VBD
incubated/VBN
under/IN
splicing/NN
conditions/NNS
with/IN
TP/NN
RNA/NN
./.
====================
RT-PCR/NN
analyses/NNS
were/VBD
then/RB
showed/VBD
that/IN
an/DT
amplified/VBN
fragment/NN
of/IN
the/DT
expected/VBN
size/NN
of/IN
102/CD
bp/NN
was/VBD
generated/VBN
from/IN
reaction/NN
mixtures/NNS
with/IN
TP/NN
RNA/NN
and/CC
Rib96/NN
(/(
Fig/NN
./.
====================
3B/NN
,/,
lane/NN
3/CD
)/)
./.
====================
However/RB
,/,
no/DT
such/JJ
RT-PCR/NN
products/NNS
were/VBD
generated/VBN
from/IN
either/CC
sample/NN
with/IN
TP/NN
RNA/NN
alone/RB
or/CC
Rib73/NN
alone/RB
(/(
Fig/NN
./.
====================
3B/NN
,/,
lane/NN
5/CD
or/CC
6/CD
)/)
./.
====================
Moreover/RB
,/,
no/DT
RT-PCR/NN
products/NNS
were/VBD
produced/VBN
in/IN
the/DT
reaction/NN
with/IN
inactive/JJ
ribozyme/NN
,/,
R/NN
(/(
d/FW
)/)
73/CD
,/,
and/CC
TP/NN
RNA/NN
(/(
Fig/NN
./.
====================
3B/NN
,/,
lane/NN
4/CD
)/)
./.
====================
These/DT
results/NNS
suggest/VBP
that/IN
the/DT
amplified/VBN
RT-PCR/NN
products/NNS
in/IN
the/DT
lane/NN
3/CD
of/IN
Fig/NN
./.
====================
3B/NN
resulted/VBD
from/IN
the/DT
catalytic/JJ
activity/NN
of/IN
the/DT
specific/JJ
ribozyme/NN
./.
====================
Sequence/NN
analyses/NNS
of/IN
the/DT
amplified/VBN
spliced/VBN
products/NNS
were/VBD
performed/VBN
to/TO
determine/VB
if/IN
the/DT
specific/JJ
ribozyme/NN
could/MD
accurately/RB
employ/VB
the/DT
/ra/7s-splicing/JJ
reaction/NN
with/IN
the/DT
target/NN
RNA/NN
./.
====================
The/DT
sequence/NN
of/IN
the/DT
102/CD
bp/NN
RT-PCR/NN
fragment/NN
demonstrated/VBD
that/IN
Rib73/NN
had/VBD
correctly/RB
reacted/VBD
with/IN
the/DT
TP/NN
RNA/NN
at/IN
the/DT
predicted/VBN
reaction/NN
site/NN
(/(
5/CD
’/NN
-UGGGCU/NN
)/)
and/CC
replaced/VBD
sequences/NNS
downstream/RB
of/IN
the/DT
reaction/NN
sites/NNS
with/IN
the/DT
3/CD
’/NN
exon/NN
sequences/NNS
tagged/VBN
at/IN
the/DT
3/CD
’/NN
end/NN
of/IN
the/DT
ribozyme/NN
(/(
Fig/NN
./.
====================
3C/NN
)/)
./.
====================
Therefore/RB
,/,
it/PRP
was/VBD
concluded/VBN
that/IN
the/DT
specific/JJ
ribozyme/NN
,/,
Rib73/NN
,/,
could/MD
replace/VB
TP/NN
RNA/NN
with/IN
a/DT
3/CD
’/NN
exon/NN
attached/VBD
to/TO
the/DT
3/CD
’/NN
end/NN
of/IN
the/DT
ribozyme/NN
by/IN
targeted/VBN
trans-/NN
splicing/NN
with/IN
high/JJ
fidelity/NN
in/IN
====================
vitro/FW
./.
====================
Induction/NN
of/IN
transgene/NN
activity/NN
in/IN
TP-expressing/JJ
cells/NNS
by/IN
the/DT
specific/JJ
frans^splicing/NN
ribozyme/NN
====================
To/TO
determine/VB
whether/IN
the/DT
specific/JJ
ribozyme/NN
could/MD
modify/VB
the/DT
TP/NN
RNA/NN
to/TO
induce/VB
an/DT
intended/JJ
transgene/NN
activity/NN
in/IN
cells/NNS
,/,
we/PRP
first/RB
modified/VBN
the/DT
ribozyme/NN
construct/NN
with/IN
a/DT
functional/JJ
active/JJ
form/NN
since/IN
group/NN
I/NN
ribozymes/NNS
with/IN
only/RB
a/DT
6-nt-long/JJ
IGS/NN
have/VBP
been/VBN
very/RB
inactive/JJ
when/WRB
expressed/VBN
in/IN
mammalian/JJ
cells/NNS
(/(
Byun/NNP
et/FW
al./FW
,/,
2003/CD
)/)
./.
====================
For/IN
use/NN
in/IN
cells/NNS
,/,
we/PRP
modified/VBD
Rib73/NN
to/TO
contain/VB
an/DT
extension/NN
====================
of/IN
P1/NN
helix/NN
,/,
addition/NN
of/IN
7-nt-long/JJ
P10/NN
helix/NN
and/CC
a/DT
300-nt-long/JJ
antisense/JJ
sequence/NN
against/IN
the/DT
downstream/JJ
region/NN
of/IN
U73/NN
of/IN
the/DT
TP/NN
RNA/NN
(/(
Fig/NN
./.
====================
4A/CD
)/)
./.
====================
These/DT
modifications/NNS
have/VBP
been/VBN
demonstrated/VBN
to/TO
increase/VB
specificity/NN
and/CC
activity/NN
of/IN
the/DT
group/NN
I/NN
ribozyme/NN
in/IN
cells/NNS
(/(
Kohler/NN
et/FW
al./FW
,/,
1999/CD
)/)
./.
====================
In/IN
addition/NN
,/,
for/IN
a/DT
transgene/NN
to/TO
be/VB
readily/RB
expressed/VBN
in/IN
mammalian/JJ
cells/NNS
,/,
a/DT
new/JJ
start/NN
codon/NN
AUG/NN
with/IN
Kozak/NN
sequences/NNS
was/VBD
inserted/VBN
into/IN
the/DT
5/CD
’/NN
end/NN
of/IN
the/DT
3/CD
’/NN
exon/NN
transgene/NN
since/IN
the/DT
target/NN
sequence/NN
(/(
U96/NN
)/)
was/VBD
present/JJ
in/IN
the/DT
leader/NN
region/NN
./.
====================
The/DT
expression/NN
vector/NN
====================
encoding/VBG
the/DT
modified/VBN
//^/7S/NN
“/CD
splicing/NN
ribozyme/NN
with/IN
Flue/NN
sequence/NN
as/IN
its/PRP$
3/CD
’/NN
exon/NN
was/VBD
denoted/VBN
pRib73AS-Fluc3/NN
./.
====================
For/IN
the/DT
functional/JJ
analysis/NN
of/IN
the/DT
specific/JJ
ribozyme/NN
in/IN
cells/NNS
,/,
we/PRP
cotransfected/VBD
a/DT
plasmid/NN
encoding/VBG
TP/NN
(/(
TP-fl/JJ
or/CC
TP-orf/NN
)/)
with/IN
pRib73AS-Fluc/NN
into/IN
NIH3T3/NN
cells/NNS
(/(
Fig/NN
./.
====================
4B/NN
)/)
./.
====================
We/PRP
then/RB
assessed/VBN
transgene/NN
induction/NN
by/IN
monitoring/VBG
luciferase/NN
activity/NN
of/IN
Flue/NN
relative/JJ
to/TO
Rluc/JJ
used/VBN
for/IN
normalization/NN
./.
====================
TP-fl/JJ
is/VBZ
an/DT
expression/NN
plasmid/NN
encoding/VBG
====================
full-length/JJ
cDNA/NN
of/IN
TP/NN
,/,
thus/RB
containing/VBG
the/DT
target/NN
residue/NN
(/(
U73/NN
)/)
./.
====================
However/RB
,/,
TP-orf/NN
does/VBZ
not/RB
harbor/VB
the/DT
target/NN
sequence/NN
since/IN
it/PRP
encodes/VBZ
only/RB
open/JJ
reading/NN
frame/NN
sequence/NN
of/IN
TP/NN
./.
====================
Transfection/NN
of/IN
pRib73AS-Fluc/NN
alone/RB
(/(
-TP/NN
)/)
showed/VBD
a/DT
slight/JJ
expression/NN
of/IN
Auc/JJ
./.
====================
This/DT
nonspecific/JJ
expression/NN
could/MD
be/VB
due/JJ
to/TO
direct/JJ
translation/NN
of/IN
exon/NN
sequences/NNS
and/or/CC
translation/NN
of/IN
self-splicing/VBG
products/NNS
./.
====================
Further/RB
studies/NNS
will/MD
be/VB
needed/VBN
to/TO
elucidate/VB
the/DT
molecular/JJ
====================
mechanism/NN
of/IN
this/DT
little/JJ
nonspecific/JJ
translation/NN
./.
====================
In/IN
contrast/NN
,/,
pRib73AS-Fluc/NN
efficiently/RB
stimulated/VBN
luciferase/NN
activity/NN
by/IN
about/RB
more/RBR
than/IN
2-fold/JJ
in/IN
cells/NNS
cotransfected/VBN
with/IN
TP—fl/JJ
,/,
compared/VBN
to/TO
the/DT
cells/NNS
transfected/VBN
with/IN
the/DT
ribozyme/NN
alone/RB
(/(
Fig/NN
./.
====================
4B/NN
)/)
./.
====================
In/IN
sharp/JJ
contrast/NN
,/,
pRib73AS-Fluc/NN
could/MD
not/RB
trigger/VB
the/DT
FLuc/NN
expression/NN
in/IN
cells/NNS
cotransfected/VBN
with/IN
TP-orf/NN
(/(
Fig/NN
./.
====================
4C/NN
)/)
./.
====================
This/DT
could/MD
result/VB
from/IN
the/DT
absence/NN
of/IN
U73/NN
in/IN
the/DT
target/NN
RNA/NN
expressed/VBN
from/IN
TP-orf/NN
./.
====================
Therefore/RB
,/,
these/DT
results/NNS
strongly/RB
indicate/VBP
that/IN
the/DT
expression/NN
of/IN
the/DT
transgene/NN
by/IN
the/DT
/ra/7s-splicing/JJ
ribozyme/NN
in/IN
cells/NNS
could/MD
be/VB
highly/RB
triggered/VBN
with/IN
target/NN
RNA-specific/JJ
manner/NN
./.
====================
To/TO
determine/VB
whether/IN
the/DT
transgene/NN
induction/NN
in/IN
cells/NNS
with/IN
the/DT
specific/JJ
ribozyme/NN
would/MD
be/VB
due/JJ
to/TO
the/DT
Z/^/7s-splicing/JJ
reaction/NN
of/IN
Rib73AS-Fluc/NN
with/IN
TP/NN
RNA/NN
with/IN
fidelity/NN
in/IN
cells/NNS
,/,
we/PRP
cotransfected/VBD
pRib73AS-Fluc/NN
with/IN
TP-fl/JJ
in/IN
NIH3T3/NN
cells/NNS
(/(
Fig/NN
./.
====================
4C/NN
)/)
./.
====================
Total/JJ
RNA/NN
was/VBD
isolated/VBN
from/IN
the/DT
transfected/VBN
cells/NNS
and/CC
analyzed/VBD
by/IN
RT-PCR/NN
./.
====================
A/DT
/ra/7s-spliced/JJ
product/NN
of/IN
expected/VBN
size/NN
(/(
350/CD
bp/NN
)/)
was/VBD
detected/VBN
only/RB
in/IN
cells/NNS
cotransfected/VBN
with/IN
the/DT
ribozyme/NN
vector/NN
and/CC
TP-fl/JJ
(/(
Fig/NN
./.
====================
4C/NN
,/,
lane/NN
3/CD
)/)
./.
====================
By/IN
contrast/NN
,/,
no/DT
such/JJ
product/NN
was/VBD
generated/VBN
in/IN
cells/NNS
mock-transfected/VBD
or/CC
transfected/VBN
with/IN
the/DT
target/NN
plasmid/NN
alone/RB
,/,
the/DT
ribozyme/NN
vector/NN
alone/RB
,/,
or/CC
the/DT
inactive/JJ
ribozyme/NN
alone/RB
(/(
Fig/NN
./.
====================
4C/NN
,/,
lanes/NNS
2/CD
and/CC
5-7/CD
)/)
./.
====================
Moreover/RB
,/,
no/DT
product/NN
was/VBD
also/RB
detected/VBN
in/IN
cells/NNS
cotransfected/VBN
with/IN
the/DT
inactive/JJ
ribozyme/NN
plasmid/NN
(/(
pR/NN
(/(
d/FW
)/)
73-Fluc/JJ
)/)
and/CC
TP-fl/JJ
(/(
Fig/NN
./.
====================
4C/NN
,/,
lane/NN
4/CD
)/)
./.
====================
Sequence/NN
analysis/NN
of/IN
the/DT
amplified/VBN
fragment/NN
showed/VBD
exact/JJ
Zra/7s^splicing/VBG
of/IN
the/DT
ribozyme/NN
with/IN
U73/NN
residue/NN
of/IN
the/DT
TP/NN
RNA/NN
in/IN
cells/NNS
(/(
data/NNS
not/RB
shown/VBN
)/)
./.
====================
Thus/RB
,/,
these/DT
results/NNS
suggested/VBD
that/IN
the/DT
specific/JJ
group/NN
I/NN
ribozyme/NN
was/VBD
able/JJ
to/TO
modify/VB
the/DT
target/NN
TP/NN
RNA/NN
to/TO
highly/RB
induce/VBP
transgene/NN
activity/NN
in/IN
mammalian/JJ
cells/NNS
with/IN
/razjs-splicing/JJ
reaction/NN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
showed/VBD
that/IN
TP/NN
RNA/NN
could/MD
be/VB
a/DT
valid/JJ
gastric/JJ
cancer/NN
marker/NN
./.
====================
In/IN
addition/NN
,/,
we/PRP
developed/VBD
a/DT
specific/JJ
group/NN
I/NN
intron/NN
ribozyme/NN
to/TO
modify/VB
such/JJ
a/DT
specific/JJ
target/NN
RNA/NN
associated/VBN
with/IN
human/JJ
disease/NN
to/TO
selectively/RB
induce/VBP
transgene/NN
activity/NN
in/IN
cells/NNS
./.
====================
The/DT
3/CD
’/NN
exon/NN
can/MD
be/VB
exchanged/VBN
with/IN
any/DT
RNA/NN
sequence/NN
in/IN
the/DT
/ra^s-splicing/JJ
reaction/NN
(/(
Sullenger/NNP
and/CC
Cech/JJ
,/,
1995/CD
)/)
,/,
Thus/RB
,/,
any/DT
new/JJ
RNAs/NNS
with/IN
anti-cancer/JJ
therapeutic/JJ
activity/NN
,/,
for/IN
example/NN
,/,
cytotoxin/NN
RNA/NN
,/,
can/MD
be/VB
highly/RB
and/CC
selectively/RB
expressed/VBN
in/IN
TP-expressing/JJ
cancer/NN
cells/NNS
,/,
if/IN
they/PRP
are/VBP
tagged/VBN
at/IN
the/DT
ribozyme/NN
backbone/RB
containing/VBG
IGS/NN
identified/VBD
here/RB
./.
====================
The/DT
ribozyme/NN
could/MD
then/RB
remove/VBP
target/NN
TP/NN
RNA/NN
and/CC
simultaneously/RB
deliver/RB
cytotoxin/NN
activity/NN
selectively/RB
in/IN
cancer/NN
cells/NNS
expressing/VBG
the/DT
RNA/NN
./.
====================
Therefore/RB
,/,
this/DT
RNA/NN
replacement/NN
may/MD
be/VB
an/DT
attractive/JJ
approach/NN
for/IN
cancer/NN
therapy/NN
because/IN
it/PRP
should/MD
inhibit/VB
or/CC
reduce/VB
the/DT
production/NN
of/IN
the/DT
TP/NN
protein/NN
and/CC
simultaneously/RB
engender/VBP
the/DT
production/NN
of/IN
therapeutic/JJ
gene/NN
activity/NN
much/RB
higher/JJR
and/CC
selectively/RB
in/IN
the/DT
TP-associated/JJ
cancer/NN
cells/NNS
./.
====================
Specific/JJ
messages/NNS
associated/VBN
with/IN
a/DT
wide/JJ
range/NN
of/IN
human/JJ
====================
diseases/NNS
are/VBP
now/RB
being/VBG
intensively/RB
identified/VBN
through/IN
the/DT
functional/JJ
genomics/NNS
and/CC
bioinformatic/JJ
studies/NNS
./.
====================
Together/RB
with/IN
these/DT
advances/NNS
,/,
Zra/7^-splicing/VBG
ribozymes/NNS
that/DT
can/MD
modify/VB
the/DT
disease-associated/JJ
unique/JJ
transcripts/NNS
would/MD
be/VB
general/JJ
tools/NNS
for/IN
the/DT
treatment/NN
of/IN
diverse/JJ
human/JJ
diseases/NNS
such/JJ
as/IN
cancer/NN
./.
====================
